Sonesson C - Search Results

1

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.

Lundin A, Dietrichs E, Haghighi S, Göller ML, Heiberg A, Loutfi G, Widner H, Wiktorin K, Wiklund L, Svenningsson A, Sonesson C, Waters N, Waters S, Tedroff J. Lundin A, et al. Among authors: sonesson c. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. doi: 10.1097/WNF.0b013e3181ebb285. Clin Neuropharmacol. 2010. PMID: 20616707 Clinical Trial.

2

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.

Waters S, Tedroff J, Ponten H, Klamer D, Sonesson C, Waters N. Waters S, et al. Among authors: sonesson c. J Huntingtons Dis. 2018;7(1):1-16. doi: 10.3233/JHD-170267. J Huntingtons Dis. 2018. PMID: 29480206 Free PMC article. Review.

3

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

Pettersson F, Pontén H, Waters N, Waters S, Sonesson C. Pettersson F, et al. Among authors: sonesson c. J Med Chem. 2010 Mar 25;53(6):2510-20. doi: 10.1021/jm901689v. J Med Chem. 2010. PMID: 20155917

4

In vivo pharmacology of the dopaminergic stabilizer pridopidine.

Ponten H, Kullingsjö J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, Waters S, Waters N. Ponten H, et al. Among authors: sonesson c. Eur J Pharmacol. 2010 Oct 10;644(1-3):88-95. doi: 10.1016/j.ejphar.2010.07.023. Epub 2010 Jul 24. Eur J Pharmacol. 2010. PMID: 20667452 Free article.

5

The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.

Ponten H, Kullingsjö J, Sonesson C, Waters S, Waters N, Tedroff J. Ponten H, et al. Among authors: sonesson c. Eur J Pharmacol. 2013 Jan 5;698(1-3):278-85. doi: 10.1016/j.ejphar.2012.10.039. Epub 2012 Nov 2. Eur J Pharmacol. 2013. PMID: 23127496

6

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.

Sjöberg F, Waters S, Löfberg B, Sonesson C, Waters N, Tedroff J. Sjöberg F, et al. Among authors: sonesson c. Pharmacol Res Perspect. 2021 May;9(3):e00792. doi: 10.1002/prp2.792. Pharmacol Res Perspect. 2021. PMID: 34018344 Free PMC article. Clinical Trial.

7

First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.

Rein-Hedin E, Sjöberg F, Waters S, Sonesson C, Waters N, Huss F, Tedroff J. Rein-Hedin E, et al. Among authors: sonesson c. Clin Pharmacol Drug Dev. 2021 Dec;10(12):1485-1494. doi: 10.1002/cpdd.959. Epub 2021 Jun 12. Clin Pharmacol Drug Dev. 2021. PMID: 34118179 Free article. Clinical Trial.

8

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains.

Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N, Tedroff J, Långström B. Ekesbo A, et al. Among authors: sonesson c. Neuropharmacology. 1999 Mar;38(3):331-8. doi: 10.1016/s0028-3908(98)00200-7. Neuropharmacology. 1999. PMID: 10219971

9

Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease.

Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A. Tedroff J, et al. Among authors: sonesson c. Neurology. 1999 Oct 22;53(7):1605-6. doi: 10.1212/wnl.53.7.1605. Neurology. 1999. PMID: 10534281 No abstract available.

10

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties.

Dyhring T, Nielsen EØ, Sonesson C, Pettersson F, Karlsson J, Svensson P, Christophersen P, Waters N. Dyhring T, et al. Among authors: sonesson c. Eur J Pharmacol. 2010 Feb 25;628(1-3):19-26. doi: 10.1016/j.ejphar.2009.11.025. Epub 2009 Nov 15. Eur J Pharmacol. 2010. PMID: 19919834

11

Synthesis, pharmacological evaluation and QSAR modeling of mono-substituted 4-phenylpiperidines and 4-phenylpiperazines.

Pettersson F, Svensson P, Waters S, Waters N, Sonesson C. Pettersson F, et al. Among authors: sonesson c. Eur J Med Chem. 2013 Apr;62:241-55. doi: 10.1016/j.ejmech.2012.12.031. Epub 2013 Jan 5. Eur J Med Chem. 2013. PMID: 23353756

12

Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.

Mattsson C, Andreasson T, Waters N, Sonesson C. Mattsson C, et al. Among authors: sonesson c. J Med Chem. 2012 Nov 26;55(22):9735-50. doi: 10.1021/jm300975f. Epub 2012 Oct 17. J Med Chem. 2012. PMID: 23043306

13

Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.

Pettersson F, Svensson P, Waters S, Waters N, Sonesson C. Pettersson F, et al. Among authors: sonesson c. J Med Chem. 2012 Apr 12;55(7):3242-9. doi: 10.1021/jm201692d. Epub 2012 Mar 23. J Med Chem. 2012. PMID: 22385498

14

Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.

Waters S, Sonesson C, Svensson P, Tedroff J, Carta M, Ljung E, Gunnergren J, Edling M, Svanberg B, Fagerberg A, Kullingsjö J, Hjorth S, Waters N. Waters S, et al. Among authors: sonesson c. J Pharmacol Exp Ther. 2020 Jul;374(1):113-125. doi: 10.1124/jpet.119.264226. Epub 2020 May 1. J Pharmacol Exp Ther. 2020. PMID: 32358046

15

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.

Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators. Svenningsson P, et al. Among authors: sonesson c. Mov Disord. 2020 Jun;35(6):1046-1054. doi: 10.1002/mds.28020. Epub 2020 Mar 21. Mov Disord. 2020. PMID: 32198802 Clinical Trial.

16

On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression.

Hansson LO, Waters N, Holm S, Sonesson C. Hansson LO, et al. Among authors: sonesson c. J Med Chem. 1995 Aug 4;38(16):3121-31. doi: 10.1021/jm00016a015. J Med Chem. 1995. PMID: 7636874

17

Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography.

Neu H, Hartvig P, Torstenson R, Fasth KJ, Sonesson C, Waters N, Carlsson A, Tedroff J, Långström B. Neu H, et al. Among authors: sonesson c. Nucl Med Biol. 1997 Aug;24(6):507-11. doi: 10.1016/s0969-8051(97)00023-1. Nucl Med Biol. 1997. PMID: 9316077

18

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.

Svenningsson P, Johansson A, Nyholm D, Tsitsi P, Hansson F, Sonesson C, Tedroff J. Svenningsson P, et al. Among authors: sonesson c. NPJ Parkinsons Dis. 2018 Dec 6;4:35. doi: 10.1038/s41531-018-0071-3. eCollection 2018. NPJ Parkinsons Dis. 2018. PMID: 30534585 Free PMC article.

19

Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour.

Waters N, Löfberg L, Haadsma-Svensson S, Svensson K, Sonesson C, Carlsson A. Waters N, et al. Among authors: sonesson c. J Neural Transm Gen Sect. 1994;98(1):39-55. doi: 10.1007/BF01277593. J Neural Transm Gen Sect. 1994. PMID: 7710738

20

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity.

Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A, Neu H, Fasth KJ, Långström B. Tedroff J, et al. Among authors: sonesson c. Synapse. 1998 Apr;28(4):280-7. doi: 10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5. Synapse. 1998. PMID: 9517836

21

Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.

Ekesbo A, Andrén PE, Gunne LM, Sonesson C, Tedroff J. Ekesbo A, et al. Among authors: sonesson c. Eur J Pharmacol. 2000 Feb 18;389(2-3):193-9. doi: 10.1016/s0014-2999(99)00879-1. Eur J Pharmacol. 2000. PMID: 10688984

22

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

Sonesson C, Lin CH, Hansson L, Waters N, Svensson K, Carlsson A, Smith MW, Wikström H. Sonesson C, et al. J Med Chem. 1994 Aug 19;37(17):2735-53. doi: 10.1021/jm00043a013. J Med Chem. 1994. PMID: 8064801

23

Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.

Sonesson C, Waters N, Svensson K, Carlsson A, Smith MW, Piercey MF, Meier E, Wikström H. Sonesson C, et al. J Med Chem. 1993 Oct 15;36(21):3188-96. doi: 10.1021/jm00073a021. J Med Chem. 1993. PMID: 8230107

24

In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery.

Waters S, Svensson P, Kullingsjö J, Pontén H, Andreasson T, Sunesson Y, Ljung E, Sonesson C, Waters N. Waters S, et al. Among authors: sonesson c. ACS Chem Neurosci. 2017 Apr 19;8(4):785-797. doi: 10.1021/acschemneuro.6b00371. Epub 2017 Jan 9. ACS Chem Neurosci. 2017. PMID: 27997108 Free article.

25

(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent.

Hjorth S, Waters S, Waters N, Tedroff J, Svensson P, Fagerberg A, Edling M, Svanberg B, Ljung E, Gunnergren J, McLean SL, Grayson B, Idris NF, Neill JC, Sonesson C. Hjorth S, et al. Among authors: sonesson c. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419. doi: 10.1124/jpet.120.000037. Epub 2020 Jun 30. J Pharmacol Exp Ther. 2020. PMID: 32605972

26

The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition.

Nilsson M, Carlsson A, Markinhuhta KR, Sonesson C, Pettersson F, Gullme M, Carlsson ML. Nilsson M, et al. Among authors: sonesson c. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):677-85. doi: 10.1016/j.pnpbp.2004.05.004. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15276693

27

Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT(6) receptor agonists.

Mattsson C, Svensson P, Boettcher H, Sonesson C. Mattsson C, et al. Among authors: sonesson c. Eur J Med Chem. 2013 May;63:578-88. doi: 10.1016/j.ejmech.2013.03.006. Epub 2013 Mar 14. Eur J Med Chem. 2013. PMID: 23542166

28

A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.

Mattsson C, Svensson P, Sonesson C. Mattsson C, et al. Among authors: sonesson c. Eur J Med Chem. 2014 Feb 12;73:177-86. doi: 10.1016/j.ejmech.2013.11.035. Epub 2013 Dec 15. Eur J Med Chem. 2014. PMID: 24393810

29

2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.

Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, Leibrock J, Böttcher H. Mattsson C, et al. Among authors: sonesson c. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4. doi: 10.1016/j.bmcl.2005.06.067. Bioorg Med Chem Lett. 2005. PMID: 16055331

30

Potential anxiolytic properties of R-(+)-8-OSO2CF3-PAT, a 5-HT 1A receptor agonist.

Barf T, Korte SM, Korte-Bouws G, Sonesson C, Damsma G, Bohus B, Wikström H. Barf T, et al. Among authors: sonesson c. Eur J Pharmacol. 1996 Feb 22;297(3):205-11. doi: 10.1016/0014-2999(95)00782-2. Eur J Pharmacol. 1996. PMID: 8666051

31

Effects of the dopamine autoreceptor antagonist (-)-DS121 on the discriminative stimulus properties of d-amphetamine and cocaine.

Clark D, Exner M, Furmidge LJ, Svensson K, Sonesson C. Clark D, et al. Among authors: sonesson c. Eur J Pharmacol. 1995 Feb 24;275(1):67-74. doi: 10.1016/0014-2999(94)00747-u. Eur J Pharmacol. 1995. PMID: 7774664

32

Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.

Sonesson C, Barf T, Nilsson J, Dijkstra D, Carlsson A, Svensson K, Smith MW, Martin IJ, Duncan JN, King LJ, et al. Sonesson C, et al. J Med Chem. 1995 Apr 14;38(8):1319-29. doi: 10.1021/jm00008a010. J Med Chem. 1995. PMID: 7731017

33

Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.

Sonesson C, Boije M, Svensson K, Ekman A, Carlsson A, Romero AG, Martin IJ, Duncan JN, King LJ, Wikström H. Sonesson C, et al. J Med Chem. 1993 Oct 29;36(22):3409-16. doi: 10.1021/jm00074a022. J Med Chem. 1993. PMID: 8230131

34

Regiochemical Control and Suppression of Double Bond Isomerization in the Heck Arylation of 1-(Methoxycarbonyl)-2,5-dihydropyrrole.

Sonesson C, Larhed M, Nyqvist C, Hallberg A. Sonesson C, et al. J Org Chem. 1996 Jul 12;61(14):4756-4763. doi: 10.1021/jo952112s. J Org Chem. 1996. PMID: 11667407

35

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.

Kosiborod M, Gause-Nilsson I, Xu J, Sonesson C, Johnsson E. Kosiborod M, et al. Among authors: sonesson c. J Diabetes Complications. 2017 Jul;31(7):1215-1221. doi: 10.1016/j.jdiacomp.2017.02.001. Epub 2017 Feb 10. J Diabetes Complications. 2017. PMID: 28284707

36

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.

Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Sonesson C, et al. Cardiovasc Diabetol. 2016 Feb 19;15:37. doi: 10.1186/s12933-016-0356-y. Cardiovasc Diabetol. 2016. PMID: 26895767 Free PMC article.

37

[Reply on compensation for egg donation: Two year trial--will be evaluated].

Sonesson CJ, Tribo G, Giwercman A. Sonesson CJ, et al. Lakartidningen. 2013 Nov 20-26;110(47):2126. Lakartidningen. 2013. PMID: 24437110 Swedish. No abstract available.

38

Self-administered symphysis-fundus measurements analyzed with a novel statistical method for detection of intrauterine growth restriction: a clinical evaluation.

Bergman E, Axelsson O, Petzold M, Sonesson C, Kieler H. Bergman E, et al. Among authors: sonesson c. Acta Obstet Gynecol Scand. 2011 Aug;90(8):890-6. doi: 10.1111/j.1600-0412.2011.01181.x. Epub 2011 Jun 20. Acta Obstet Gynecol Scand. 2011. PMID: 21564029 Free article.

39

Relative growth estimated from self-administered symphysis fundal measurements.

Bergman E, Axelsson O, Kieler H, Sonesson C, Petzold M. Bergman E, et al. Among authors: sonesson c. Acta Obstet Gynecol Scand. 2011 Feb;90(2):179-85. doi: 10.1111/j.1600-0412.2010.01026.x. Epub 2010 Dec 7. Acta Obstet Gynecol Scand. 2011. PMID: 21241264 Free article.

40

A recycling framework for the construction of Bonferroni-based multiple tests.

Burman CF, Sonesson C, Guilbaud O. Burman CF, et al. Among authors: sonesson c. Stat Med. 2009 Feb 28;28(5):739-61. doi: 10.1002/sim.3513. Stat Med. 2009. PMID: 19142850

41

Self-administered measurement of symphysis-fundus heights.

Bergman E, Kieler H, Petzold M, Sonesson C, Axelsson O. Bergman E, et al. Among authors: sonesson c. Acta Obstet Gynecol Scand. 2007;86(6):671-7. doi: 10.1080/00016340701258867. Acta Obstet Gynecol Scand. 2007. PMID: 17520397 Free article.

42

A CUSUM framework for detection of space-time disease clusters using scan statistics.

Sonesson C. Sonesson C. Stat Med. 2007 Nov 20;26(26):4770-89. doi: 10.1002/sim.2898. Stat Med. 2007. PMID: 17476652

43

Are flexible designs sound?

Burman CF, Sonesson C. Burman CF, et al. Among authors: sonesson c. Biometrics. 2006 Sep;62(3):664-9; discussion 670-83. doi: 10.1111/j.1541-0420.2006.00626.x. Biometrics. 2006. PMID: 16984302

44

Symphysis-fundus measurements for detection of small for gestational age pregnancies.

Bergman E, Kieler H, Petzold MG, Sonesson C, Axelsson O. Bergman E, et al. Among authors: sonesson c. Acta Obstet Gynecol Scand. 2006;85(4):407-12. doi: 10.1080/00016340500432390. Acta Obstet Gynecol Scand. 2006. PMID: 16612701 Free article.

45

Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.

Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A. Andersson K, et al. Among authors: sonesson c. Health Policy. 2006 Dec;79(2-3):231-43. doi: 10.1016/j.healthpol.2006.01.007. Epub 2006 Feb 13. Health Policy. 2006. PMID: 16473436

46

What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden.

Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. Andersson K, et al. Among authors: sonesson c. Pharmacoepidemiol Drug Saf. 2005 May;14(5):341-8. doi: 10.1002/pds.1055. Pharmacoepidemiol Drug Saf. 2005. PMID: 15624198

47

Surveillance in longitudinal models: detection of intrauterine growth restriction.

Petzold M, Sonesson C, Bergman E, Kieler H. Petzold M, et al. Among authors: sonesson c. Biometrics. 2004 Dec;60(4):1025-33. doi: 10.1111/j.0006-341X.2004.00258.x. Biometrics. 2004. PMID: 15606423

48

Expression of delta opioid receptor mRNA and protein in the rat cerebral cortex and cerebellum is decreased by growth hormone.

Persson AI, Aberg ND, Oscarsson J, Isaksson OG, Rönnbäck L, Frick F, Sonesson C, Eriksson PS. Persson AI, et al. Among authors: sonesson c. J Neurosci Res. 2003 Feb 15;71(4):496-503. doi: 10.1002/jnr.10515. J Neurosci Res. 2003. PMID: 12548705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page